Amarin to Present at the 2013 Aegis Capital Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 18, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced that John F. Thero, Amarin's President, is
scheduled to present a general company update at the 2013 Aegis Capital
Healthcare Conference in Las Vegas, NV on Thursday, September 26, 2013, at
4:30 p.m. ET (1:30 p.m. PT).
Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA and available by prescription. For more
information about Vascepa visit www.vascepa.com. For more information about
Amarin visit www.amarincorp.com.
CONTACT: Amarin contact information:
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315
Press spacebar to pause and continue. Press esc to stop.